Medicon Village, in Lund, southern Sweden, is a part of a cluster of life science analysis and improvement, along with actors such because the European Spallation Supply (ESS), the BioMedical Centre (BMC) at Lund College and the Max IV Laboratory.
Medicon Village is split into two firms – Medicon Village Fastighets AB and Medicon Village Innovation AB. Each firms are totally owned by the Mats Paulsson Foundation for Research, Innovation and Societal Development. The phrases of the Basis stipulate that any surplus should be re-invested into analysis and innovation.
On the campus, there are greater than 2,800 colleagues in additional than 180 organizations and firms. The village is residence to the well being chain from prevention and diagnostics to therapy and care. Researchers and firms there are energetic inside most cancers, diabetes, respiratory and lung ailments in addition to inflammatory ailments.
The start of the village got here from what may have been a catastrophe. In March 2010, AstraZeneca, the worldwide biopharmaceutical firm, introduced that it was closing its analysis amenities in Lund and transferring to a different a part of Sweden. This left 80,000 m² of actual property vacant. Nevertheless, there was a contented ending as Medicon Village emerged, and has turn out to be an enormous – and rising – success for the Skåne area.
Labiotech had the chance to go to the village lately, and spoke with the Innovation CEO, Petter Hartman.